Bach T et al., 2022: Population pharmacokinetic-pharmacodynamic model built from two phase 1 oxfendazole trials, including a food effect and a small inhibitory effect on red-cell synthesis. The authors conclude a low risk of a haemoglobin safety concern even at 60 mg/kg daily.
The effect of oxfendazole exposure on hemoglobin concentration in healthy adults was characterized by a life span indirect response model in which oxfendazole has positive but minor inhibitory effect on red blood cell synthesis.
Bach T et al., 2022: Population pharmacokinetic-pharmacodynamic model built from two phase 1 oxfendazole trials, including a food effect and a small inhibitory effect on red-cell synthesis. The authors conclude a low risk of a haemoglobin safety concern even at 60 mg/kg daily. Modelling study using data from two phase 1 trials (N=70 single ascending dose and N=36 multiple ascending dose/food effect); United States (University of Iowa); oxfendazole 0.5-60 mg/kg. Funder: NIAID/NIH and NCATS. Declared conflicts: none recorded. Comparator: none (model). Relevant to C1 (food effect on absorption) and to C3 (a measured, minor erythropoietic effect of the metabolite in humans). Study type: other.
